Related Experiment Video
Updated: Jun 13, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Why pleiotropic interventions are needed for Alzheimer's disease
Sally A Frautschy1, Greg M Cole
1Geriatric Research and Clinical Center, Greater Los Angeles Healthcare System, Veteran's Administration, Los Angeles, USA. frautsch@ucla.edu
Molecular Neurobiology
|May 4, 2010
Summary
Alzheimer's disease (AD) treatments need stage-specific interventions. Pleiotropic drugs targeting multiple AD pathways, like omega-3 fatty acids and curcumin, show promise for addressing complex pathology.
Area of Science:
- Neuroscience
- Pathology
- Pharmacology
Background:
- Alzheimer's disease (AD) pathogenesis involves beta-amyloid (Abeta) accumulation and aberrant amyloid precursor protein (APP) processing, initiating a cascade.
- Understanding early events preceding cognitive decline is crucial for developing effective AD prevention and treatment strategies.
- Existing knowledge gaps hinder the development of timely interventions, despite understanding factors initiating AD decades before symptoms.
Purpose of the Study:
- To investigate stage-specific interventions for Alzheimer's disease (AD).
- To explore the potential of pleiotropic drugs, such as omega-3 fatty acids and curcumin, in addressing multiple AD pathological pathways.
- To challenge the monotherapy approach by proposing combination therapies for parallel pathological events in AD.
Main Methods:
- Review of existing literature on AD pathogenesis and therapeutic strategies.
- Hypothesizing the need for interventions addressing both early pathogenesis and downstream damage.
- Focusing on the pleiotropic activities of omega-3 fatty acids and curcumin in various AD models.
Main Results:
- Monotherapy targeting single steps in AD cascade has yielded disappointing results.
- Pathological events in AD, including plaque and tangle formation, occur in parallel by the mild cognitive impairment (MCI) stage.
- Pleiotropic agents like omega-3 fatty acids and curcumin exhibit anti-inflammatory, antioxidant, and anti-amyloid activities relevant to AD.
Conclusions:
- Stage-specific and pleiotropic interventions are necessary for effective Alzheimer's disease (AD) treatment.
- Combination therapies targeting parallel pathological pathways offer a more promising approach than monotherapy.
- Omega-3 fatty acids and curcumin demonstrate potential as multi-target agents for AD due to their diverse beneficial activities.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...